Clinical Trial Update: Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) [Phase 2]

View source ↗

Summary

Phase 2 study of vorinostat combined with bortezomib in relapsed or refractory multiple myeloma completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2021-04-01